Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ryan Weisman who wrote (566)	11/20/1997 9:16:00 AM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

Ryan, Hopefully the head-start that AccuMed has obtained will continue uninterrupted. If cytopathology sales in the U.S. are to be limited as a result of an unclear advantage of a particular technology over another, then International sales will be the key in the short run. The critical key (for AccuMed) then becomes Leica. Leica has an international presence that may make the difference to supporting and validating the automated cyto-technology of AccuMed over the others. Until the dust settles, (which may take quite a few quarters) my feel is the international health care community should be concentrated on. Later after the U.S.- F.D.A. resolves the merits of the studies of each system, the U.S. market can be concentrated on. Obviously this is my perspective on the situation only. The in-house sales team of AccuMed is still new and as such probably don't have an evolved distribution-channel infrastructure. The timing of the general market uncertainty in the U.S. regarding one system over another may provide the time to develop that infrastructure. Meanwhile Leica it seems has the ball for AccuMed at this point in the game. Their desire and dedication to promoting international sales of the AcCell/TracCell will determine AccuMed's continued viability as a player in this sector. That is why I have stated that I am glad that the microbiology division sales are increasing. But....then also look at that crowded playing field. Fortunately Mr. Gombrich's many years of experience in product development has taught him that mutiple playing fields are needed in the developing of new untried products. Remember the rest of the domestic players are trying to "forge ahead" in changing an established protocol. As such they will have to expend a considerable amount of resources in doing so. AccuMed by virtue of augmenting the time-established protocol is hopefully able to do so at a reduced cost in their limited resources. Frank

To: Ryan Weisman who wrote (566)	11/24/1997 12:48:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

AccuMed projected 5 year EPS growth at 50% annualized. The mean earnings per share (EPS) estimate is derived from all polled analysts' estimates of what the company's earnings (profits) per share will be five years from now. Right there with Amazon.Com (AMZN) the internet book seller that has gone ballistic in share price. Why does the buying public believe that Amazon will increase 50% annualy yet acts like they have never heard of AccuMed? The sector average of 4,024 companies is 19.4%. Source - Morningstar morningstar.net The company??? at least is telling analysts' that they are expecting some robust sales down the pike. Let's hope that these projections are not pie in the sky. In the past two quarters the analysts' appeared to have been given some numbers that have not been in the same ball park that AccuMed has been playing. Eventually you would think there would be a pleasant quarterly surprise, wouldn't you? Has anyone been in talks with the IR @ ACMI lately to provide some insight to the strength or weakness in sales so far? The second month (in the quarter) is almost closed with one month left for (Q-4-'97). How many hits, runs and errors are we looking at in the bottom of the sixth inning? Frank